• The optimism regarding the potential of IFN as an antiviral therapeutic agent has not been fulfilled
• Achievements made during recent years indicate that IFN-alpha should be regarded as an important part of the therapeutic arsenal in malignant diseases.
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Interferon (IFN) was originally d escribed more than 40 years ago by Isaacs and Lindeman as a substance that is produced upon stimulation of cells by viruses, and that has the abi lity to protect cells from infection with viruses of any kind, that is to interfere with viral infections. The antiviral a ctivity of IFN was thus found to be nonspecific, a fact that led to the idea that IFN might be used therapeutically against all kinds of viral infections. The revolution that antibiotics had meant for bacterial infections, it was reasoned, might be paralleled by therapeutic use of IFN in viral infections
The optimism regarding the potential of IFN as an antiviral therapeutic agent has not been fulfilled and for various reasons it is not until during the last decade that IFN has been established as a potent antiviral agent in chronic viral infections. In parallel with being the object of antiviral research, however, IFN has also been studied with regard to its anti-tumour properties, and it is today becoming a standard treatment in certain malignant diseases. IFN:s are part of the innate immunological defence and are produced after introduction in to the body of foreign substances. In particular, viruses have the ability to evoke production of IFN:s but also bacteria, fungi and other "nonself" agents may induce IFN produ ction. IFN-alpha and IFN-beta are very rapidly produced upon stimulation whereas IFN-gamma, which is a major constituent of the antigen-specific T cell response, may be produced at a somewhat later stage of immune r esponses. However, since NK cells, which are not induced in an antigenspecific manner, also produce IFNgamma, the formation of this cytokine may also be an early event following stimulation with infectious agents. semi-purified preparations of IFNalpha obtained from human cultures of leukocytes that had been stimulated with a paramyxovirus (Sendai virus). After the cloning of IFN genes it became possible to use DNA recombinant techniques to produce large amounts of purified IFN:s in an inexpensive way. Using another line of investigation it was demonstrated that certain lines of lymphoblastoid cells constitutively produced large amounts of IFN-alpha, and these could thus be used for the pr oduction of large amounts of IFN.
Different types of interferons

Mechanisms of action
Presently, there are the following three main types of IFN -alpha preparations that are commercially available.
• Recombinant IFN-alpha2 preparations, which dominate the market are available in different forms of which IFN-alpha2b (Intron A Ò , Schering-Plough) and IFN-alpha2a (Roferon Ò , Roche) have undergone the most extensive clinical trials and are the most widely used.
• Lymphoblastoid IFN-alpha (e.g. Wellferon Ò , Glaxo-Wellcome) co ntains a variety of IFN -alpha subtypes and is produced by lymphoblastoid cells that are grown in large tanks.
• 
Therapeutic use of interferons Side effects
Interferons are substances that are produced in the body and have potent biological actions. Many of the symptoms associated with acute viral infections are apparently caused by interferons that are produced in large qua ntities during the infection, since the symptoms can be reproduced after pa renteral administration of exogenous interferon. The common side effects of IFN treatment i.e. the "influenza-like" symptoms fever, chills, nausea fatigue, myalgia and loss of appetite are thus expected events that occur in most subjects, with a severity that depend on the dosage used. These types of side effects usually show a tendency to be less severe with time and are usually tolerable. Other side effects include mental depression which will prompt discontinuation of treatment, alopecia and weight loss. These side effects are, however uncommon, as is also appea rance of thyroid dysfunction. The latter, that is associated with appearance of thyroid autoantibodies, usually disappears after cessation of IFN-alpha therapy. The risk for autoimmunity appears to be grater following trea tment with IFN-gamma than with IFNalpha, however, and IFN-gamma treatment has even been described to be associated with development of systemic herpes erythematodes.
Use of IFN-alpha in viral diseases
Acute viral infections
Several trials have been performed in acute viral infections most notably in upper respiratory infections. Since the peak of viral replication, and also the peak of the body's own interferon response usually occurs simultaneously with or before the appearance of symptoms, therapy with exogenous inte rferon at this stage is not likely to markedly change the course of the infection. In accordance with this notion topical application of IFN-alpha in e.g. viral upper respiratory infections has not been considered to be worthwhile. In very severe acute infections, such as Lassa fever, IFN -alpha therapy has been advocated and in some cases claimed to be successful.
Although IFN is usually relatively ineffective in acute viral infections it has been successfully used for the prevention of respiratory infections in exposed individuals. The side effects fo llowing intranasal application of IFNalpha, such as nose bleeding, however, have precluded its general use as a preventive measure, and likewise, the side effects appearing after parenteral administration of IFN -alpha are us ually considered to outweigh the pote ntial benefits of preventive use of IFN:s.
Persistent viral infections
In contrast to acute infections, chronic viral infections are often amenable to IFN therapy. Among these hepatitis C virus (HCV) and hepatitis B virus (HBV) infections are the most important and IFN-alpha is currently a standard treatment in HCV and HBV i nfections.
Large clinical trials have been pe rformed using various types and do sages of IFN-alpha in HCV infections. The trials have been monitored using two types of markers, i.e. serum transaminases and HCV-RNA, the latter being a measure of the virus itself. Quantitative measurements have shown that IFN-alpha therapy results in a rapid initial decline of HCV serum levels followed by a phase of more slowly decreasing levels, that eventually leads to total disappearance of HCV-RNA after several weeks or months of continued treatment in responding individuals. Even after complete virological (disappearance of HCV-RNA) and biochemical (normalisation of liver transaminases) responses, however, there is frequently a relapse of the infection following cessation of treatment.
Using the initially tried dose of 3 million units of IFN-alpha three times a week for a period of 6 months, there was usually a response rate of 40-50% at end of treat ment but at follow-up 6 months later about half of the initially responding patients had relapsed. Later studies have shown that it is possible to increase the rate of su stained response significantly by increasing the time of treatment to 12 months and/or by using an initial, so called induction, treatment with daily administration of higher doses of IFNalpha.
Recently the standard treatment for HCV infection has been changed to include Ribavirin as an addition to IFNalpha. As compared to 6 month mon otherapy with IFN-alpha the sustained response rates using the combination therapy have been found to generally be at least twice as high i.e. 40-50%. Combination therapy is recommended in particular for patients with a high viral load (i.e. more than 2-3 million HCV-RNA copies per ml) and for those who have relapsed following IFN-alpha monotherapy. It is also claimed that patients harbouring certain genotypes of HCV that are considered difficult to treat (notably genotype 1b) should u ndergo primary treatment with the combination of IFN-alpha + Ribavirin.
Although the presently used therapeutic regimen´s in HCV infection fr equently fail to eradicate the virus, they may still be worthwhile. Several studies, most notably one from Japan, have now suggested that the risk of develo ping hepatocellular cancer may be considerably reduced by IFN treatment, even in cases of persistent infection.
HBV infections may be treated with IFN-alpha. A multitude of studies have showed that treatment with IFN-alpha results in an average response of about 40% measured as a change from eantigen positivity to anti -e positivity (seroconversion) or disappearance of detectable HBV-DNA from the blood. The patients that respond best to treatment are those that have an ongoing immunological response manifested as raised aminotransferase levels and moderate amounts of HBV-DNA in their blood. Generally, it is considered that patients in other stages of the di sease, such as in the immunotolerant phase or in late cirrhotic stage respond less well or are resistant to IFN -alpha treatment.
The doses used in HBV infection are usually higher than those generally used in HCV infection and the dur ation of treatment is usually shorter. Similar response rates, i.e. 40% or higher, may be obtained in children.
During recent years new drugs, in particular nucleoside analogues like Lamivudine Ò or acyclovir-like drugs such as Famciclovir Ò have been found to have profound effects on the replication of HBV. However, the effects of such drugs are usually not long -lasting.
Thus, although HBV-DNA has been found to rapidly decrease following i nstitution of antiviral therapy it has promptly reappeared in the circulation following cessation of treatment. The difference be tween IFN-alpha and the antiviral drugs in this respect has been interpreted to indicate that the effect of IFN-alpha in HBV-infection is primarily immunomodulatory rather than antiviral. In order to obtain a persistent effect on the hepatitis an immunological action, resulting in a seroconversion (from e-to an-e-positivity) would be necessary. Therefore, trials have been made with a combination of IFN-alpha and antiviral drugs. Future therapy in hepatitis B may possibly, similarly as in hepatitis C, be based on combination therapy.
Hepatitis B and C are the only viral i nfections where, presently, IFN-alpha is used as a standard treatment. Clear effects on the replication in vivo of HIV-1 have been obtained but since the effect of IFN-alpha in HIV infection generally are inferior to those of currently used nucleoside analogues and prot ease inhibitors, IFN:s have not become a part of the standard treatment in this disease. In HIV-infection complicated by Kaposi´s sarcoma, however, IFN-alpha may be used therapeutically. Advantage is in this case taken of both the antitumoral and antiviral and perhaps also of the immunological effects of IFN-alpha.
For similar reasons as in Kaposi´s sa rcoma IFN-alpha can be used for treatment of papilloma virus infections, both in cases of larynx papilloma and in cases of skin or genital warts. In larynx papilloma, however, a permanent cure is difficult to achieve with this treatment and intralesional injection of IFN-alpha into warts, which is the drug administration of choice is cu mbersome and frequently only partially effective. Recent large clinical studies have convincingly demonstrated the beneficial effect of two types of recombinant IFNbeta, the glycosylated IFN-beta1a and the non-glycosylated IFN-beta1b carrying one amino acid deletion. Both of these have been found to decrease r elapse rates and cause reduction of l esions, detectable by magnetic resonance. Also the progression of neur ological disability has been shown in some studies.
Interferon-b in multiple sclerosis
The obvious beneficial effects of IFNbeta in MS might be paralleled by similar effects of IFN-alpha. This, however, has not been sufficiently well explored and presently, IFN-alpha is not recommended for use in MS.
Therapeutic use of IFN-gamma IFN-gamma is a potent stimulator of cell-mediated (Th1) immunity. As a consequence of this it may have detrimental effects on Th1 -cell mediated autoimmune diseases, such as MS or type 1 diabetes mellitus. On the other hand, any disease that is associated with defective cell -mediated immunity may be a potential target for IFNgamma therapy. The most prominent indication for IFN-gamma, and the one that has been considered to justify a pproval by medical products agencies in many countries, is chronic granulomatous disease that is associated with a severe lack of IFN production. Good results with IFN-gamma therapy have been obtained e.g. in severe mycobacterial infections and mycoses. IFNgamma has also been tried in atopic dermatitis and in rheumatoid arthritis, but the results have not been un iformly convincing.
Interferon therapy in malignant diseases
Studies of IFN therapy in tumors have in the majority of cases been conducted using various preparations of IFNalpha. Early studies in osteosarcoma gave promising results and showed that rather crude preparations of leukocyte (natural) IFN-alpha at doses of 3 million units 3 times a week could be given for months-years without causing intolerable side effects. Similarly, the early trials showed that larynx papilloma could be successfully treated with these preparations although r elapses after cessation of treatment were common. Generally the doses of IFN-alpha given in malignant diseases are much higher than used in viral diseases, but the duration of treatment is shorter. High doses are chosen because it is believed that the action of IFN -alpha is that of an antiproliferative, cytostatic, drug. Although this may be true in most t umors it is also possible that immuno-
IFNgamma is a potent stimulator of cell-mediated (Th1) immunity"
logic effects, such as stimulation of cytotoxic cells, may plan an important role in certain tumors, and lower doses of IFN-alpha may then possibly be r equired to obtain good effects.
An example of the use of lower doses of IFN-alpha is the currently performed clinical studies of triple therapy with low-dose IFN-alpha, interleukin-2 and histamine in malignant melanoma. This disease is poorly sensitive to treatment with IFN-alpha alone but using the mentioned combination of drugs, which is designed to evoke a maximal stimulation of natural killer (NK) cells, a very si gnificant effect on the survival can be achieved.
IFN-alpha has been used as adjuvant therapy, i.e. after surgical removal of primary tumors to prevent develo pment of metastases. Significant effects on the time to relapse and on overall survival of recombinant IFN-alpha have been achieved in malignant melanoma. Generally, however, the side e ffects associated with the high dose regimen are severe. Several studies are presently performed in order to explore the possibilities of using lower doses of recombinant or natural IFNalpha for adjuvant therapy in malignant melanoma.
Achievements made during recent years indicate that IFN-alpha should be regarded as an important part of the therapeutic arsenal in malignant diseases. It seems likely that during the coming years the indications for therapy with IFN-alpha, alone and in combination with a variety of other drugs will be extended to comprise a large variety of malignant diseases.
